Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: Effects of antihypertensive therapy

Journal of Internal Medicine

Volumn 256, Issue 4, 2004, Pages 331-337

  Nadar, S K ^a   Blann, A D ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Angiopoietin 1; Calcium channel blockers; Hypertension; P selectin; Platelet; Vascular endothelial growth factor

Indexed keywords

AMLODIPINE; ANGIOPOIETIN 1; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PADGEM PROTEIN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODYNAMICS; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME;

AMLODIPINE; ANGIOPOIETIN-1; ANTIHYPERTENSIVE AGENTS; BLOOD PLATELETS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; P-SELECTIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 4644234870     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2004.01367.x     Document Type: Article

References (29)

1. Felmeden DC, Spencer CG, Chung NA et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). Am J Cardiol 2003; 92: 400-5.
2. Kiefer FN, Neysari S, Humar R, Li W, Munk VC, Battegay EJ. Hypertension and Angiogenesis. Curr Pharm Design 2003; 9: 1733-44.
3. Felmeden DC, Spencer CG, Belgore FM, Blann AD, Beevers DG, Lip GY. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 2003; 16: 11-20.
4. Noon JP, Walker BR, Webb DJ, Shore AC, Holton DW, Edwards HV. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest 1997; 99; 1873-9.
5. Struijker Boudier HAJ, Le Noble JLML, Messing MWJ, Huijberts MSP, Le Noble FAC, Van Essen H. The microcirculation in hypertension. J Hypertens 1992; 10(Suppl. 7): 147-56.
6. Verheul HM, Hoekman K, Luykx-de Bakker S et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3: 2187-90.
7. Li JJ, Huang YQ, Basch R, Karpatkin S. Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost 2001; 85: 204-6.
8. Salgado R, Benoy I, van Marck E, Vermeulen P, Dirix L. The importance of the VEGF-load in platelets in cancer patients. Ann Oncol 2002; 13: 1689-90.
9. Selheim F, Holmsen H, Vassbotn FS. Identification of functional VEGF receptors on human platelets. FEBS Lett 2002; 512: 107-10.
10. Islim IF, Bareford D, Ebanks M, Beevers DG. The role of platelets in essential hypertension. Blood Press 1995; 4: 199-214.
11. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62.
12. Hernandez-Hernandez R, Armas-Padilla MC, Velasco M et al. Effects of amlodipine and enalapril on platelet function in patients with mild to moderate hypertension. Int J Clin Pharmacol Ther 1999; 37: 323-31.
13. Pirich C, Schmid P, Fitscha P, Wytek R, O'Grady J, Sinzinger H. Influence of calcium antagonists on platelet function and vascular prostacyclin production. Blood Press Suppl 1994; 1: 75-80.
14. Hernandez R, Carvajal AR, Armas-de Hernandez MJ et al. Effects of amlodipine on platelet aggregation and blood pressure in patients with essential hypertension. Clin Ther 1993; 15: 304-13.
15. Hernandez R, Carvajal AR, Armas-de Hernandez MJ et al. The effects of the calcium antagonist amlodipine on blood pressure and platelet aggregation in hypertensive patients. Postgrad Med J 1991; 67(Suppl. 5): S38-40.
16. Kamath S, Blann AD, Caine GJ, Gurney D, Chin BS, Lip GY. Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation. Stroke 2002; 33: 1237-42.
17. O'Brien E, Asmar R, Beilin L et al. European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21: 821-48.
18. Sever PS, Dahlof B, Poulter NR et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 2001; 19: 1139-47.
19. Werther K, Christensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002; 62: 343-50.
20. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell specific receptor tyrosine kinases: VEGFs, angiopoietins, and ehrins in vascular development. Genes Dev 1999; 13: 1055-66.
21. Blann AD, Lip GYH. Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis 1997; 128: 135-8.
22. Siess W. Molecular mechanisms of platelet activation. Physiol Rev 1989; 69: 158-78.
23. Rink TJ, Sage SO. Calcium signalling in human platelets. Annu Rev Physiol 1990; 52: 431-49.
24. Fasolato C, Innocenti B, Pozzan T. Receptor activated calcium influx: how many mechanisms for how many channels. Trends Pharmacol Sci 1994; 15: 77-83.
25. Ryback MEM, Renzulli LA. Effect of calcium channel blockers on platelet GpIIb-IIIa as a calcium channel in liposomes: comparison with effects on the intact platelets. Thromb Haemost 1992; 67: 131-6.
26. Celletti FL, Hilfiker PR, Ghafouri P, Dake MD. Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque. J Am Coll Cardiol 2001; 37: 2126-30.
27. Lemstrom KB, Krebs R, Nykanen AI et al. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 2002; 105: 2524-30.
28. Dulak J, Jozkowicz A, Frick M et al. Vascular endothelial growth factor: angiogenesis, atherogenesis or both? J Am Coll Cardiol 2001; 38: 2137-8.
29. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7: 425-9.